Protagonist Therapeutics Inc
PTGX80.220USD
+0.020+0.02%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
5.01BMarket Cap
103.29P/E TTM
More Details of Protagonist Therapeutics Inc Company
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Protagonist Therapeutics Inc Info
Ticker SymbolPTGX
Company nameProtagonist Therapeutics Inc
IPO dateAug 11, 2016
CEOPatel (Dinesh V)
Number of employees126
Security typeOrdinary Share
Fiscal year-endAug 11
Address7707 Gateway Blvd Ste 140
CityNEWARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94560-1160
Phone15104740170
Websitehttps://www.protagonist-inc.com/
Ticker SymbolPTGX
IPO dateAug 11, 2016
CEOPatel (Dinesh V)
Company Executives of Protagonist Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.16K
-440.00%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+14147.00%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+10725.00%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-1756.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-5130.00%
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-5130.00%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.16K
-440.00%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+14147.00%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+10725.00%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-1756.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-5130.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Nov 19
Updated: Wed, Nov 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
Other
56.19%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
Other
56.19%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.24%
Investment Advisor/Hedge Fund
36.00%
Hedge Fund
27.18%
Research Firm
5.73%
Venture Capital
4.41%
Private Equity
1.74%
Pension Fund
1.09%
Individual Investor
1.01%
Bank and Trust
0.33%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
565
72.46M
115.91%
-7.78M
2025Q3
551
71.95M
115.09%
-3.63M
2025Q2
533
68.00M
109.30%
-9.94M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
8.02M
12.83%
-434.20K
-5.13%
Sep 30, 2025
Farallon Capital Management, L.L.C.
6.20M
9.91%
+24.00K
+0.39%
Sep 30, 2025
RTW Investments L.P.
5.76M
9.21%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
4.25M
6.79%
-101.37K
-2.33%
Sep 30, 2025
State Street Investment Management (US)
3.17M
5.06%
-41.75K
-1.30%
Sep 30, 2025
BVF Partners L.P.
2.56M
4.1%
-650.13K
-20.25%
Sep 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.92%
--
--
Sep 30, 2025
Wellington Management Company, LLP
1.91M
3.05%
+870.71K
+83.90%
Sep 30, 2025
UBS Financial Services, Inc.
1.89M
3.03%
-608.94K
-24.35%
Sep 30, 2025
Deep Track Capital LP
1.72M
2.74%
-1.53M
-47.14%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco S&P SmallCap Health Care ETF
2.82%
Invesco S&P SmallCap 600 Pure Growth ETF
2.71%
Invesco Dorsey Wright Healthcare Momentum ETF
2.33%
ALPS Medical Breakthroughs ETF
1.99%
ETC 6 Meridian Small Cap Equity ETF
1.56%
State Street SPDR S&P Biotech ETF
1.44%
Cambria Value and Momentum ETF
1.16%
Invesco S&P SmallCap Momentum ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
Direxion Daily S&P Biotech Bull 3X Shares
0.88%
View more
Invesco S&P SmallCap Health Care ETF
Proportion2.82%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion2.71%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.33%
ALPS Medical Breakthroughs ETF
Proportion1.99%
ETC 6 Meridian Small Cap Equity ETF
Proportion1.56%
State Street SPDR S&P Biotech ETF
Proportion1.44%
Cambria Value and Momentum ETF
Proportion1.16%
Invesco S&P SmallCap Momentum ETF
Proportion1%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.94%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.88%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Protagonist Therapeutics Inc?
The top five shareholders of Protagonist Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A. holds 8.02M shares, accounting for 12.83% of the total shares.
Farallon Capital Management, L.L.C. holds 6.20M shares, accounting for 9.91% of the total shares.
RTW Investments L.P. holds 5.76M shares, accounting for 9.21% of the total shares.
The Vanguard Group, Inc. holds 4.25M shares, accounting for 6.79% of the total shares.
State Street Investment Management (US) holds 3.17M shares, accounting for 5.06% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.02M shares, accounting for 12.83% of the total shares.
Farallon Capital Management, L.L.C. holds 6.20M shares, accounting for 9.91% of the total shares.
RTW Investments L.P. holds 5.76M shares, accounting for 9.21% of the total shares.
The Vanguard Group, Inc. holds 4.25M shares, accounting for 6.79% of the total shares.
State Street Investment Management (US) holds 3.17M shares, accounting for 5.06% of the total shares.
What are the top three shareholder types of Protagonist Therapeutics Inc?
The top three shareholder types of Protagonist Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
How many institutions hold shares of Protagonist Therapeutics Inc (PTGX)?
As of 2025Q4, 565 institutions hold shares of Protagonist Therapeutics Inc, with a combined market value of approximately 72.46M, accounting for 115.91% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.82%.
What is the biggest source of revenue for Protagonist Therapeutics Inc?
In --, the -- business generated the highest revenue for Protagonist Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
